Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX vs Chemoradiation in Locally Advanced Rectal Cancer
NCT02288195Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2014
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in rectal cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Local-regional failure-free survival at 5 years. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02288195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288195.